GLYRX-PF Drug Patent Profile
✉ Email this page to a colleague
When do Glyrx-pf patents expire, and when can generic versions of Glyrx-pf launch?
Glyrx-pf is a drug marketed by Exela Pharma and is included in one NDA.
The generic ingredient in GLYRX-PF is glycopyrrolate. There are seventeen drug master file entries for this compound. Sixty-one suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Glyrx-pf
A generic version of GLYRX-PF was approved as glycopyrrolate by AM REGENT on July 23rd, 1986.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for GLYRX-PF?
- What are the global sales for GLYRX-PF?
- What is Average Wholesale Price for GLYRX-PF?
Summary for GLYRX-PF
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 105 |
| Patent Applications: | 5,032 |
| Drug Prices: | Drug price information for GLYRX-PF |
| What excipients (inactive ingredients) are in GLYRX-PF? | GLYRX-PF excipients list |
| DailyMed Link: | GLYRX-PF at DailyMed |
Pharmacology for GLYRX-PF
| Drug Class | Anticholinergic Cholinergic Muscarinic Antagonist |
| Mechanism of Action | Cholinergic Antagonists Cholinergic Muscarinic Antagonists |
US Patents and Regulatory Information for GLYRX-PF
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exela Pharma | GLYRX-PF | glycopyrrolate | SOLUTION;INTRAMUSCULAR, INTRAVENOUS | 210997-001 | Jul 11, 2018 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Exela Pharma | GLYRX-PF | glycopyrrolate | SOLUTION;INTRAMUSCULAR, INTRAVENOUS | 210997-003 | Apr 9, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Exela Pharma | GLYRX-PF | glycopyrrolate | SOLUTION;INTRAMUSCULAR, INTRAVENOUS | 210997-002 | Jul 11, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Exela Pharma | GLYRX-PF | glycopyrrolate | SOLUTION;INTRAMUSCULAR, INTRAVENOUS | 210997-004 | Dec 14, 2020 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
